1887

Abstract

Surveillance of invasive meningococcal diseases (IMD) must be carried out regularly and continuously in order to detect the emergence of strains of reduced susceptibility to antibiotics for therapeutic and prophylactic use and the appearance of new invasive clones. Molecular-typing approaches allow reliable traceability and powerful epidemiological analysis. This is an epidemiological study of causing meningitis in Casablanca, Morocco. The grouping was confirmed by PCR mainly on the isolates from cerebrospinal fluid (CSF). A total of 245 confirmed isolates of were obtained between 2010 and 2019 of which 93 % are of group B. Overall, 24 % of all the isolates have a reduced susceptibility to penicillin G, but no resistance to penicillin G has been reported. All the isolated strains are susceptible to third-generation cephalosporins (3GCs). Genotyping by multilocus sequence typing (MLST) of a selection of 18 strains showed that the majority of isolates belong to the invasive clonal complex CC 32(9/18) followed by the CC 41/44(3/18).

Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000157
2020-07-22
2020-09-28
Loading full text...

Full text loading...

/deliver/fulltext/acmi/10.1099/acmi.0.000157/acmi000157.html?itemId=/content/journal/acmi/10.1099/acmi.0.000157&mimeType=html&fmt=ahah

References

  1. Harrison LH, Pelton SI, Wilder-Smith A, Holst J, Safadi MAP et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29:3363–3371 [CrossRef][PubMed]
    [Google Scholar]
  2. Agnememel A, Hong E, Giorgini D, Nuñez-Samudio V, Deghmane A-E et al. Neisseria meningitidis serogroup X in sub-Saharan Africa. Emerg Infect Dis 2016; 22:698–702 [CrossRef][PubMed]
    [Google Scholar]
  3. Borrow R, Caugant DA, Ceyhan M, Christensen H, Dinleyici EC et al. Meningococcal disease in the middle East and Africa: findings and updates from the global meningococcal initiative. J Infect 2017; 75:1–11 [CrossRef][PubMed]
    [Google Scholar]
  4. Jones DM, Sutcliffe EM. Meningococci with reduced susceptibility to penicillin. Lancet 1990; 335:863–864 [CrossRef][PubMed]
    [Google Scholar]
  5. Nadel S. Treatment of meningococcal disease. J Adolesc Health 2016; 59:S21–S28 [CrossRef][PubMed]
    [Google Scholar]
  6. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012; 799:1–20 [CrossRef][PubMed]
    [Google Scholar]
  7. Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines 2017; 16:313–328 [CrossRef][PubMed]
    [Google Scholar]
  8. M100-S11, performance standards for antimicrobial susceptibility testing. Clin Microbiol Newsl 2001; 23:49 [CrossRef]
    [Google Scholar]
  9. Taha MK. Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis. J Clin Microbiol 2000; 38:855–857 [CrossRef][PubMed]
    [Google Scholar]
  10. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95:3140–3145 [CrossRef][PubMed]
    [Google Scholar]
  11. Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013; 13:416–425 [CrossRef][PubMed]
    [Google Scholar]
  12. Tali-Maamar H, Rahal K. Étude de souches de Neisseria meningitidis isolées en Algérie entre 1992 et 2001. Médecine et Maladies Infectieuses 2003; 33:640–643 [CrossRef]
    [Google Scholar]
  13. Brik A, Terrade A, Hong E, Deghmane A, Taha MK et al. Phenotypic and genotypic characterization of meningococcal isolates in Tunis, Tunisia: high diversity and impact on vaccination strategies. Int J Infect Dis 2020; 91:73–78 [CrossRef][PubMed]
    [Google Scholar]
  14. Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother 2013; 9:162–171 [CrossRef][PubMed]
    [Google Scholar]
  15. Thabuis A, Tararbit K, Taha M-K, Dejour-Salamanca D, Ronin V et al. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination. Eurosurveillance 2018; 23:1700590 [CrossRef]
    [Google Scholar]
  16. Zerouali K, Elmdaghri N, Boudouma M, Benbachir M, Serogroups BM. Serogroups, serotypes, serosubtypes and antimicrobial susceptibility of Neisseria meningitidis isolates in Casablanca, Morocco. Eur J Clin Microbiol Infect Dis 2002; 21:483–485 [CrossRef][PubMed]
    [Google Scholar]
  17. Razki A, Hong E, Zerouali K, Belabbes H, Aitmouss K et al. Molecular characterization of invasive isolates of Neisseria meningitidis in Casablanca, Morocco. J Clin Microbiol 2018; 56: 25 06 2018 [CrossRef][PubMed]
    [Google Scholar]
  18. Saguer A, Smaoui H, Taha M-K, Kechrid A. Characterization of invasive Neisseria meningitidis strains isolated at the children's Hospital of Tunis, Tunisia. East Mediterr Health J 2016; 22:343–349 [CrossRef][PubMed]
    [Google Scholar]
  19. Maamar HT, Laliam R, Guettou B, Rahal K. Molecular typing and antibiotic sensitivity of Neisseria meningitidis strains isolates in Algeria. 27th ECCMID 2017Vienna, Autria22-25 April 2017 p 2112
    [Google Scholar]
  20. Parent du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect 2017; 74:564–574 [CrossRef][PubMed]
    [Google Scholar]
  21. Hong E, Barret A-S, Terrade A, Denizon M, Antona D et al. Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France. J Infect 2018; 76:149–158 [CrossRef][PubMed]
    [Google Scholar]
  22. Caniça M, Dias R, Nunes B, Carvalho L, Ferreira E et al. Invasive culture-confirmed Neisseria meningitidis in Portugal: evaluation of serogroups in relation to different variables and antimicrobial susceptibility (2000–2001). J Med Microbiol 2004; 53:921–925 [CrossRef][PubMed]
    [Google Scholar]
  23. Garrido-Estepa M, Guzman M, Portero R. Enfermedad meningocócica en España. Análisis de la temporada 2012–2013; 2014
  24. Ministère de la Santé, Maroc Guide de la lutte contre les méningites bactériennes communautaires, Juin 2010. www.sante.gov.ma 07 FEBRUARY 2020
  25. Memish ZA, Shibl AM. Consensus building and recommendations based on the available epidemiology of meningococcal disease in Gulf cooperation Council states. Travel Med Infect Dis 2011; 9:60–66 [CrossRef][PubMed]
    [Google Scholar]
  26. Lucidarme J, Hill DMC, Bratcher HB, Gray SJ, du Plessis M et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect 2015; 71:544–552 [CrossRef][PubMed]
    [Google Scholar]
  27. Frank T, Hong E, Mbecko J-R, Lombart J-P, Taha M-K et al. Emergence of Neisseria meningitidis Serogroup W, Central African Republic, 2015–2016. Emerg Infect Dis 2018; 24:2080–2083 [CrossRef][PubMed]
    [Google Scholar]
  28. Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: a systematic literature review. Int J Infect Dis 2019; 85:37–48 [CrossRef][PubMed]
    [Google Scholar]
  29. Fukusumi M, Kamiya H, Takahashi H, Kanai M, Hachisu Y et al. National surveillance for meningococcal disease in Japan, 1999–2014. Vaccine 2016; 34:4068–4071 [CrossRef][PubMed]
    [Google Scholar]
  30. Bröker M, Emonet S, Fazio C, Jacobsson S, Koliou M et al. Meningococcal serogroup Y disease in Europe: continuation of high importance in some European regions in 2013. Hum Vaccin Immunother 2015; 11:2281–2286 [CrossRef][PubMed]
    [Google Scholar]
  31. Ruedin HJ, Ninet B, Pagano E, Rohner P. Epidemiology of meningococcal disease in Switzerland, 1999–2002. Eur J Clin Microbiol Infect Dis 2004; 23:517–522 [CrossRef][PubMed]
    [Google Scholar]
  32. Ferreira E, Dias R, Caniça M. Antimicrobial susceptibility, serotype and genotype distribution of meningococci in Portugal, 2001-2002. Epidemiol Infect 2006; 134:1203–1207 [CrossRef][PubMed]
    [Google Scholar]
  33. Bertrand S, Carion F, Wintjens R, Mathys V, Vanhoof R. Evolutionary changes in antimicrobial resistance of invasive Neisseria meningitidis isolates in Belgium from 2000 to 2010: increasing prevalence of penicillin nonsusceptibility. Antimicrob Agents Chemother 2012; 56:2268–2272 [CrossRef][PubMed]
    [Google Scholar]
  34. Antignac A, Ducos-Galand M, Guiyoule A, Pirès R, Alonso J-M et al. Neisseria meningitidis strains isolated from invasive infections in France (1999–2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis 2003; 37:912–920 [CrossRef][PubMed]
    [Google Scholar]
  35. Sorhouet-Pereira C, Efron A, Gagetti P, Faccone D, Regueira M et al. Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010. PLoS One 2013; 8:e58065 [CrossRef][PubMed]
    [Google Scholar]
  36. Vacca P, Fazio C, Neri A, Ambrosio L, Palmieri A et al. Neisseria meningitidis Antimicrobial Resistance in Italy, 2006 to 2016. Antimicrob Agents Chemother 2018; 62:AAC.00207–00218 [CrossRef]
    [Google Scholar]
  37. Gorla MC, Pinhata JMW, Dias UJ, de Moraes C, Lemos AP. Surveillance of antimicrobial resistance in Neisseria meningitidis strains isolated from invasive cases in Brazil from 2009 to 2016. J Med Microbiol 2018; 67:750–756 [CrossRef][PubMed]
    [Google Scholar]
  38. Pascual A, Joyanes P, Martinez-Martinez L, Suarez AI, Perea EJ. Comparison of broth microdilution and E-test for susceptibility testing of Neisseria meningitidis. J Clin Microbiol 1996; 34:588–591 [CrossRef][PubMed]
    [Google Scholar]
  39. Brown EM, Fisman DN, Drews SJ, Dolman S, Rawte P et al. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother 2010; 54:1016–1021 [CrossRef][PubMed]
    [Google Scholar]
  40. Gorla MCO, de Paiva MV, Salgueiro VC, Lemos APS, Brandão AP et al. Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008. Enferm Infecc Microbiol Clin 2011; 29:85–89 [CrossRef][PubMed]
    [Google Scholar]
  41. Mounchetrou Njoya I, Deghmane A, Taha M, Isnard H, Parent du Chatelet I et al. A cluster of meningococcal disease caused by rifampicin-resistant C meningococci in France, April 2012. Euro Surveill 2012; 17:20254[PubMed]
    [Google Scholar]
  42. Zerouali K, Castelli P, Van Looveren M, El Mdaghri N, Boudouma M et al. Étude de souches de Neisseria meningitidis sérogroupe B isolées à Casablanca PAR multilocus sequence typing et électrophorèse en CHAMP pulsé. Pathol Biol 2006; 54:166–170 [CrossRef]
    [Google Scholar]
  43. Silva LA, Coronato B, Schlackman J, Marsh JW, Ezeonwuka C et al. Neisseria meningitidis disease-associated clones in Amazonas State, Brazil. Infect Dis 2018; 50:697–704 [CrossRef]
    [Google Scholar]
  44. Abad R, Medina V, Stella M, Boccadifuoco G, Comanducci M et al. Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries. PLoS One 2016; 11:e0150721 [CrossRef][PubMed]
    [Google Scholar]
  45. Feil EJ, Maiden MC, Achtman M, Spratt BG. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol Biol Evol 1999; 16:1496–1502 [CrossRef][PubMed]
    [Google Scholar]
  46. Jolley KA, Kalmusova J, Feil EJ, Gupta S, Musilek M et al. Carried meningococci in the Czech Republic: a diverse recombining population. J Clin Microbiol 2000; 38:4492–4498 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000157
Loading
/content/journal/acmi/10.1099/acmi.0.000157
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error